● Not Yet Recruiting

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events

Condition: Elevated Lipoprotein(a) · Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

PhasePhase 2

Planned participants120

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a randomized, double-blind, placebo-controlled Phase II trial evaluating the efficacy and safety of oral SAL0137 in adults with elevated Lp(a) and high cardiovascular risk. Participants will be randomized 1:1:1:1 to receive low-dose SAL0137, medium-dose SAL0137, high-dose SAL0137, or placebo for a treatment period of 12 weeks. The study assesses changes in Lp(a) levels and safety parameters.

This description comes directly from the study's public registry record.

Talk to the study team

Li · 13521531013 · 13521531013@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Peking University First Hospital

Beijing, Beijing Municipality, China

—

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07729475